Pfizer Inc. PFE
29.45 USD +0.09 (+0.31%)
At closeNov 11, 2026, 7:59 PM EST
29.46 +0.01 +0.03%
After hours · Nov 11, 7:59 PM ET
28.95 Day range 29.50
23.67 52-week range 30.79
- YTD
- +18.27%
- 1 year
- +15.44%
Benzinga news
benzinga.com Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the…
benzinga.com Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.
benzinga.com Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.
benzinga.com Scotiabank Maintains Sector Outperform on Pfizer, Raises Price Target to $35 Scotiabank analyst Louise Chen maintains Pfizer (NYSE:PFE) with a Sector Outperform and raises the price target from $33 to $35.
benzinga.com Citigroup Maintains Neutral on Pfizer, Raises Price Target to $30 Citigroup analyst Geoff Meacham maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $30.- benzinga.com RBC Capital Maintains Sector Perform on Pfizer, Raises Price Target to $28 RBC Capital analyst Trung Huynh maintains Pfizer (NYSE:PFE) with a Sector Perform and raises the price target from $25 to $28.
benzinga.com Amazon, Pfizer, Eaton And A Financial Stock On CNBC’s ‘Final Trades’ CNBC's Final Trades: Brown picked Amazon, Lebenthal chose BlackRock, Snipe backed Eaton, and Terranova recommended Pfizer.
benzinga.com Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone Markets closed mixed as CNN Fear & Greed stayed at 19 (Extreme Fear); Nasdaq rose 0.83%, Dow fell, Apple dropped and Aehr surged 26%.
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
benzinga.com Pfizer Q3 2026 Earnings Call Transcript Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
benzinga.com Pfizer Raises FY2026 Adj EPS Guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 Est; Raises FY2026 Sales Guidance from $60.500B-$62.500B to $62.000B-$64.000B vs $62.166B Est Pfizer (NYSE:PFE) raises FY2026 Adj EPS guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 analyst estimate. Raises FY2026 sales outlook from $60.500 billion-$62.500 billion to $62.000 billion-$64.000…- benzinga.com Pfizer Q3 Adj. EPS $0.87 Beats $0.72 Estimate, Sales $16.583B Beat $15.872B Estimate Pfizer (NYSE:PFE) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.72 by 19.18 percent. This is unchanged from the same period last year. The company…
- benzinga.com Pfizer Appoints Cecile Guegan As CFO And EVP, Effective November 1, 2026 Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experiencePfizer Inc. (NYSE:PFE) today announced that its Board of Directors…
benzinga.com Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings Pfizer will report Q3 earnings Nov. 3; analysts expect EPS to fall to $0.73 and revenue to $15.88B, while recent ratings remain mixed.
benzinga.com Nasdaq Dips Over 1% as Tech Stocks Fall: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone CNN Fear & Greed fell to 23, signaling Extreme Fear, as tech stocks dragged Nasdaq down 1.07%; Dow rose 214 points amid U.S.-Iran diplomacy hopes.
benzinga.com Pfizer, Apple and 3 Stocks to Watch Heading Into Tuesday Pfizer and Keurig Dr Pepper report earnings; Apple, Palantir and AMD draw attention after results, guidance and trading moves.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds dip to 45% as Wall Street navigates Election Day, AMD earnings, and a volatile oil market.
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com AMD Could Swing $90.7 Billion After Earnings Seven major companies are set to report earnings Tuesday, and options traders are pricing in significant stock moves. From Pfizer’s modest 4.14% implied move to Shopify’s 13.01% swing, here’s a…
benzinga.com How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings Pfizer expects Q3 EPS of 73¢ and revenue of $15.88B; its 5.64% dividend yield requires ~$106,454 to generate $500 monthly.
benzinga.com Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients Pfizer reports positive Phase 3 ELREXFIO data showing reduced disease progression risk in relapsed or refractory multiple myeloma patients.
benzinga.com Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma…- benzinga.com Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive…
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.
benzinga.com Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts Roche halts German investments as chief Daniel Steiners warns Berlin that statutory drug rebates shatter trust in the market.
benzinga.com JD Vance Touts TrumpRx Drug Price Push, Trump Accounts as ‘Economic Nationalism’ Wins Ahead Of Midterms JD Vance touted TrumpRx and Trump Accounts as key economic wins, highlighting prescription drug savings ahead of the midterm elections.
benzinga.com Pfizer Stock Hits 52-Week High: What's Going On? Pfizer Inc (NYSE:PFE) shares are climbing Thursday to a new 52-week high as drugmakers rally broadly. The move comes a week after the FDA approved a Tukysa regimen.
benzinga.com Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’ CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.- benzinga.com JP Morgan Maintains Neutral on Pfizer, Raises Price Target to $30 JP Morgan analyst Chris Schott maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $28 to $30.
benzinga.com A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.- benzinga.com Cantor Fitzgerald Maintains Neutral on Pfizer, Raises Price Target to $28 Cantor Fitzgerald analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $28.
benzinga.com Pharma Lobby Sues Trump Administration Over Medicare Drug Pricing Rule, Calls It ‘Unlawful Overreach’ — ‘The Results Are Preordained’ PhRMA sued the Trump administration over its Medicare drug pricing rule, arguing CMS exceeded its authority under federal law.
benzinga.com Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease The FDA approved Pfizer's TUKYSA combination as a front-line maintenance therapy for advanced HER2-positive breast cancer.- benzinga.com Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance optionPfizer Inc.…
benzinga.com Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims Florida files a lawsuit against Pfizer and CEO Albert Bourla over alleged deceptive vaccine marketing and undisclosed health risks.
benzinga.com Vaxcyte Stock Hits New 52-Week High - Here’s Why Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.- benzinga.com Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency Pfizer Inc. (NYSE:PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease…
benzinga.com Pfizer Says Eczema Drug Shows Significant Skin Clearance Pfizer reports positive Phase 2 trial results for tilrekimig in treating moderate-to-severe atopic dermatitis at the EADV Congress.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Full Transcript: Pfizer Q2 2026 Earnings Call Pfizer (NYSE:PFE) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call…
benzinga.com Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer Public Citizen exposes separate government drug deals with Pfizer and Eli Lilly, warning the pacts could increase global drug prices.
benzinga.com Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
benzinga.com Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
benzinga.com Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
benzinga.com Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’ Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.